Xiaoming Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiaoming Hu has a total of 263 co-authors. Here are the top co-authors by number of shared publications:
- Rehana K. Leak
Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, PA (R.K.L.).
27 shared publications - Jun Chen
Geriatric Research, Education and Clinical Center, Veterans Affairs Pittsburgh Health Care System, PA (J.L., S.H., W.Z., W.-C.W., F.Z., Q.Y., H.P., X.H., Y.S., J.C.).
24 shared publications Jun Chen
Department of Neurology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
15 shared publications- Yejie Shi
Geriatric Research, Education and Clinical Center, Veterans Affairs Pittsburgh Health Care System, PA (J.L., S.H., W.Z., W.-C.W., F.Z., Q.Y., H.P., X.H., Y.S., J.C.).
14 shared publications Fei Xu
Department of Neurology (W.M., F.X., H.P., J.S., J.L., T.-W.M., Q.T., A.P., J.B., L.J., R.A.S., J.C., X.H.), University of Pittsburgh, PA
12 shared publications- Peiying Li
Department of Anesthesiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
9 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (10) , e71118
Insights Into the Role of Platelet Factor 4 in Neurodegenerative Diseases
Background: As population aging accelerates worldwide, the prevalence and burden of neurodegenerative diseases (NDs) continue to rise, underscoring the urgent need to identify key molecular mechanisms driving disease progression and novel therapeutic targets. Chronic neuroinflammation is a hallmark of multiple NDs, including Alzheimer's disease and Parkinson's disease. Platelet factor 4 (PF4) is a chemokine primarily released by activated platelets and has traditionally been investigated for its roles in hemostasis, thrombosis, and peripheral inflammation. Results: Growing evidence has implicated PF4 in the pathogenesis of NDs. Altered PF4 expression has been observed across multiple NDs. As a central player at the intersection of the nervous, immune, and vascular systems, PF4 modulates inflammation, vascular homeostasis, and neuronal survival, all of which are critical in the pathogenesis of NDs. Dissecting the cell‐type specific and temporally dynamic roles of PF4 across diverse disease contexts is essential for elucidating its contribution to neurodegenerative processes and disease progression. Conclusion: This review highlights PF4 as a potential mechanistic mediator in NDs and discusses its promise as both a biomarker and a therapeutic target. Further elucidation of PF4 signaling pathways may provide new insights into disease mechanisms and uncover novel opportunities for targeted interventions in NDs.
- 6 October 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (10) , e71118
Open AccessInsights Into the Role of Platelet Factor 4 in Neurodegenerative Diseases
Background: As population aging accelerates worldwide, the prevalence and burden of neurodegenerative diseases (NDs) continue to rise, underscoring the urgent need to identify key molecular mechanisms driving disease progression and novel therapeutic targets. Chronic neuroinflammation is a hallmark of multiple NDs, including Alzheimer's disease and Parkinson's disease. Platelet factor 4 (PF4) is a chemokine primarily released by activated platelets and has traditionally been investigated for its roles in hemostasis, thrombosis, and peripheral inflammation. Results: Growing evidence has implicated PF4 in the pathogenesis of NDs. Altered PF4 expression has been observed across multiple NDs. As a central player at the intersection of the nervous, immune, and vascular systems, PF4 modulates inflammation, vascular homeostasis, and neuronal survival, all of which are critical in the pathogenesis of NDs. Dissecting the cell‐type specific and temporally dynamic roles of PF4 across diverse disease contexts is essential for elucidating its contribution to neurodegenerative processes and disease progression. Conclusion: This review highlights PF4 as a potential mechanistic mediator in NDs and discusses its promise as both a biomarker and a therapeutic target. Further elucidation of PF4 signaling pathways may provide new insights into disease mechanisms and uncover novel opportunities for targeted interventions in NDs.
- 1 September 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (9) , 2867-2883
Myeloid Cell–Specific Retinoid X Receptor Signaling Facilitates White Matter Repair and Stroke Recovery in Aged Mice
BACKGROUND: As stroke is the leading cause of long-term disability in the elderly, effective pharmacological therapies for neurorestoration remain an unmet clinical need. RXR (retinoid X receptor) signaling regulates inflammation and tissue repair, but the downstream repair processes linking RXR activation to stroke recovery in the aged central nervous system remain incompletely defined. We used aged mice to test the hypotheses that (1) pharmacological RXR stimulation with the brain-penetrant pan-RXR agonist bexarotene boosts poststroke recovery and (2) myeloid cell–specific RXR signaling facilitates white matter repair and underlies the therapeutic effects of bexarotene. METHODS: Permanent focal cerebral ischemia was induced in 18- to 22-month-old C57BL/6J male and female mice by distal middle cerebral artery occlusion. Pharmacological RXR activation and genetic ablation were achieved by poststroke bexarotene administration and generation of myeloid cell–specific RXR conditional knockout mice, respectively. Functional (sensorimotor and cognitive performance) and structural measures of central nervous system recovery were assessed up to 35 days after stroke. RESULTS: Poststroke treatment with bexarotene (5–10 mg/kg) improved sensorimotor performance in the rotarod, foot fault, and adhesive removal tests and alleviated cognitive deficits in the Morris water maze and passive avoidance tests. Bexarotene improved white matter integrity at 35 days after distal middle cerebral artery occlusion, without impacting white matter at 3 days or preventing gray matter atrophy at chronic injury stages. Bexarotene also suppressed immune cell infiltration and proinflammatory cytokine production, enhanced inflammation-resolving efferocytosis, promoted long-term oligodendrogenesis and angiogenesis, and fostered a prorepair central nervous system microenvironment. Accordingly, stroke outcomes were markedly worsened in aged RXR conditional knockout mice compared with age-matched wild-type mice, and the functional and white matter benefits of bexarotene were blocked in RXR conditional knockout mice. CONCLUSIONS: Myeloid RXR signaling promotes long-term stroke recovery in aged mice of both sexes and engages anti-inflammatory and prorepair mechanisms. Bexarotene warrants further evaluation as a potential neurorestorative therapy for stroke.
- 1 September 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (9) , 2867-2883
Myeloid Cell–Specific Retinoid X Receptor Signaling Facilitates White Matter Repair and Stroke Recovery in Aged Mice
BACKGROUND: As stroke is the leading cause of long-term disability in the elderly, effective pharmacological therapies for neurorestoration remain an unmet clinical need. RXR (retinoid X receptor) signaling regulates inflammation and tissue repair, but the downstream repair processes linking RXR activation to stroke recovery in the aged central nervous system remain incompletely defined. We used aged mice to test the hypotheses that (1) pharmacological RXR stimulation with the brain-penetrant pan-RXR agonist bexarotene boosts poststroke recovery and (2) myeloid cell–specific RXR signaling facilitates white matter repair and underlies the therapeutic effects of bexarotene. METHODS: Permanent focal cerebral ischemia was induced in 18- to 22-month-old C57BL/6J male and female mice by distal middle cerebral artery occlusion. Pharmacological RXR activation and genetic ablation were achieved by poststroke bexarotene administration and generation of myeloid cell–specific RXR conditional knockout mice, respectively. Functional (sensorimotor and cognitive performance) and structural measures of central nervous system recovery were assessed up to 35 days after stroke. RESULTS: Poststroke treatment with bexarotene (5–10 mg/kg) improved sensorimotor performance in the rotarod, foot fault, and adhesive removal tests and alleviated cognitive deficits in the Morris water maze and passive avoidance tests. Bexarotene improved white matter integrity at 35 days after distal middle cerebral artery occlusion, without impacting white matter at 3 days or preventing gray matter atrophy at chronic injury stages. Bexarotene also suppressed immune cell infiltration and proinflammatory cytokine production, enhanced inflammation-resolving efferocytosis, promoted long-term oligodendrogenesis and angiogenesis, and fostered a prorepair central nervous system microenvironment. Accordingly, stroke outcomes were markedly worsened in aged RXR conditional knockout mice compared with age-matched wild-type mice, and the functional and white matter benefits of bexarotene were blocked in RXR conditional knockout mice. CONCLUSIONS: Myeloid RXR signaling promotes long-term stroke recovery in aged mice of both sexes and engages anti-inflammatory and prorepair mechanisms. Bexarotene warrants further evaluation as a potential neurorestorative therapy for stroke.
- 1 July 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (7) , 2194-2207
Adiponectin Fortifies White Matter After Chronic Hypoperfusion–Induced Vascular Dementia
BACKGROUND: Vascular cognitive impairment and dementia is characterized by profound demyelination of white matter and the loss of myelin-producing oligodendrocytes. Clinical reports reveal negative correlations between plasma levels of adiponectin, the most abundant adipokine, and the severity of white matter lesions and cognitive impairments. Therefore, this study evaluated the effects of adiponectin and adipoRon, a small-molecule agonist of adiponectin receptors, on white matter integrity after chronic hypoperfusion–induced vascular cognitive impairment and dementia. METHODS: Male C57BL/6 wild-type, adiponectin knockout, and wild-type microglia-depleted (PLX5622-treated) mice were subjected to asymmetrical common carotid artery stenosis to model vascular cognitive impairment and dementia. White matter integrity was measured by immunohistochemistry, transmission electron microscopy, electrophysiology, and ex vivo diffusion tensor imaging. Cognitive functions were evaluated by Morris water maze, Y maze, and passive avoidance tests. A model of lysophosphatidylcholine/lysolecithin (LPC)-mediated demyelination using ex vivo organotypic cerebellar slice cultures was used to assess white matter repair. Primary microglia and oligodendrocytes were prepared for in vitro studies. Statistical tests ( t test or ANOVA) were based on the group numbers, types of variables, and data structure. RESULTS: Adiponectin deficiency worsened white matter lesions and impaired axonal conduction compared with wild-type mice 42 days after asymmetrical common carotid artery stenosis. Conversely, adipoRon improved white matter integrity for the long term in both young and aged mice, consistent with their superior cognitive functions after asymmetrical common carotid artery stenosis. Adiponectin and adipoRon directly protected primary oligodendrocytes against oxygen/glucose deprivation, enhanced microglial engulfment of myelin debris, and promoted oligodendrogenic capacities of microglia in vitro. AdipoRon treatment enhanced microglial engulfment of damaged myelin after asymmetrical common carotid artery stenosis and boosted oligodendrocyte regeneration and white matter integrity in a microglia-dependent manner. CONCLUSIONS: Adiponectin strengthens white matter integrity in chronic hypoperfusion–induced vascular cognitive impairment and dementia, providing a novel therapeutic target. Adiponectin may exert dual mechanistic effects by enhancing oligodendrocyte survival and promoting a reparative microglial phenotype.
- 1 July 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (7) , 2194-2207
Adiponectin Fortifies White Matter After Chronic Hypoperfusion–Induced Vascular Dementia
BACKGROUND: Vascular cognitive impairment and dementia is characterized by profound demyelination of white matter and the loss of myelin-producing oligodendrocytes. Clinical reports reveal negative correlations between plasma levels of adiponectin, the most abundant adipokine, and the severity of white matter lesions and cognitive impairments. Therefore, this study evaluated the effects of adiponectin and adipoRon, a small-molecule agonist of adiponectin receptors, on white matter integrity after chronic hypoperfusion–induced vascular cognitive impairment and dementia. METHODS: Male C57BL/6 wild-type, adiponectin knockout, and wild-type microglia-depleted (PLX5622-treated) mice were subjected to asymmetrical common carotid artery stenosis to model vascular cognitive impairment and dementia. White matter integrity was measured by immunohistochemistry, transmission electron microscopy, electrophysiology, and ex vivo diffusion tensor imaging. Cognitive functions were evaluated by Morris water maze, Y maze, and passive avoidance tests. A model of lysophosphatidylcholine/lysolecithin (LPC)-mediated demyelination using ex vivo organotypic cerebellar slice cultures was used to assess white matter repair. Primary microglia and oligodendrocytes were prepared for in vitro studies. Statistical tests ( t test or ANOVA) were based on the group numbers, types of variables, and data structure. RESULTS: Adiponectin deficiency worsened white matter lesions and impaired axonal conduction compared with wild-type mice 42 days after asymmetrical common carotid artery stenosis. Conversely, adipoRon improved white matter integrity for the long term in both young and aged mice, consistent with their superior cognitive functions after asymmetrical common carotid artery stenosis. Adiponectin and adipoRon directly protected primary oligodendrocytes against oxygen/glucose deprivation, enhanced microglial engulfment of myelin debris, and promoted oligodendrogenic capacities of microglia in vitro. AdipoRon treatment enhanced microglial engulfment of damaged myelin after asymmetrical common carotid artery stenosis and boosted oligodendrocyte regeneration and white matter integrity in a microglia-dependent manner. CONCLUSIONS: Adiponectin strengthens white matter integrity in chronic hypoperfusion–induced vascular cognitive impairment and dementia, providing a novel therapeutic target. Adiponectin may exert dual mechanistic effects by enhancing oligodendrocyte survival and promoting a reparative microglial phenotype.
- 1 May 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (5) , 1450-1463
Consensus Review of Perioperative Immune Modulation for Endovascular Thrombectomy Following Ischemic Stroke
Ischemic stroke is a major global health burden, leading to considerable mortality and long-term disability. Endovascular thrombectomy and mechanical recanalization have revolutionized acute stroke care. Nonetheless, many patients experience poor long-term neurological outcomes, which are often attributed to the no-reflow phenomenon and activation of inflammatory cascades. The perioperative period of endovascular thrombectomy, managed under either general anesthesia or conscious sedation, represents a critical window where anesthetic strategies may influence recovery through hemodynamic control and possibly immune modulation. This consensus review was generated by an international multidisciplinary expert group and synthesizes preclinical and clinical evidence to evaluate the promise of various immunomodulatory strategies for improving functional outcomes in patients with ischemic stroke following endovascular thrombectomy. Our goal is to provide a foundational reference for future research and development of novel perioperative immune therapies for patients with endovascular thrombectomy.
- 1 May 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (5) , 1450-1463
Consensus Review of Perioperative Immune Modulation for Endovascular Thrombectomy Following Ischemic Stroke
Ischemic stroke is a major global health burden, leading to considerable mortality and long-term disability. Endovascular thrombectomy and mechanical recanalization have revolutionized acute stroke care. Nonetheless, many patients experience poor long-term neurological outcomes, which are often attributed to the no-reflow phenomenon and activation of inflammatory cascades. The perioperative period of endovascular thrombectomy, managed under either general anesthesia or conscious sedation, represents a critical window where anesthetic strategies may influence recovery through hemodynamic control and possibly immune modulation. This consensus review was generated by an international multidisciplinary expert group and synthesizes preclinical and clinical evidence to evaluate the promise of various immunomodulatory strategies for improving functional outcomes in patients with ischemic stroke following endovascular thrombectomy. Our goal is to provide a foundational reference for future research and development of novel perioperative immune therapies for patients with endovascular thrombectomy.
- Open Access
- 7 April 2026
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 5 (4) , pgag106
Astrocytic frataxin deficiency drives neurocognitive impairment in sickle cell mice
Individuals with sickle cell disease (SCD) suffer from a high burden of neurocognitive impairment. Cerebrovascular lesions, characterized by diffusion tensor imaging identified neuroaxonal damage, are associated with learning and memory deficits. The molecular and cellular intermediates driving microstructural neuroaxonal damage and cognitive impairment in SCD remain largely unexplored. Herein, we report that sickle cell mice (SS) have reduced expression of frataxin (FXN), a mitochondrial protein, in their astrocytes compared with normal control (AA) mice. A newly generated sickle bone marrow chimeric mouse with astrocyte-specific deletion of FXN (SSFXN-KO) showed worsening white-matter neuroaxonal damage compared with the normal mice lacking astrocytic FXN (AAFXN-KO) as well as with the SS mice with wild-type FXN expression (SSFXN-WT). The SSFXN-KO mice exhibited impaired cognitive function assessed by the functional novel object recognition (NOR) tests. Induction of FXN improved cognitive responses in the SS mice. Overall, our data demonstrate that astrocytic FXN plays a pivotal role in regulating neuroaxonal health and cognitive function in SCD.
- 7 April 2026
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 5 (4) , pgag106
Open AccessAstrocytic frataxin deficiency drives neurocognitive impairment in sickle cell mice
Individuals with sickle cell disease (SCD) suffer from a high burden of neurocognitive impairment. Cerebrovascular lesions, characterized by diffusion tensor imaging identified neuroaxonal damage, are associated with learning and memory deficits. The molecular and cellular intermediates driving microstructural neuroaxonal damage and cognitive impairment in SCD remain largely unexplored. Herein, we report that sickle cell mice (SS) have reduced expression of frataxin (FXN), a mitochondrial protein, in their astrocytes compared with normal control (AA) mice. A newly generated sickle bone marrow chimeric mouse with astrocyte-specific deletion of FXN (SSFXN-KO) showed worsening white-matter neuroaxonal damage compared with the normal mice lacking astrocytic FXN (AAFXN-KO) as well as with the SS mice with wild-type FXN expression (SSFXN-WT). The SSFXN-KO mice exhibited impaired cognitive function assessed by the functional novel object recognition (NOR) tests. Induction of FXN improved cognitive responses in the SS mice. Overall, our data demonstrate that astrocytic FXN plays a pivotal role in regulating neuroaxonal health and cognitive function in SCD.
- Open Access
Single-cell transcriptomic analyses reveal angiogenic vascular responses to chronic cerebral hypoperfusion
- Open Access
- 17 February 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (8)
Galectin-3 mediates lysosome-related inflammation within monocyte-derived macrophages in a mouse model of ischemic brain injury
Circulating monocyte-derived macrophages (MDMø) rapidly invade the brain after stroke, exerting both detrimental and beneficial effects. Elucidating mechanisms that mediate detrimental properties of MDMø may identify therapeutic strategies to divert MDMø from destructive phenotypes, while preserving their favorable effects. Toward this goal, the current study explores the function of Galectin-3 (GAL3) in MDMø and elucidates mechanisms whereby MDMø-derived GAL3 exacerbates stroke injury. In the acutely injured brain, GAL3 expression was upregulated primarily within MDMø. Global KO of GAL3 reduced brain infarcts in the short term but did not sustain long-term positive outcomes. Using BM chimera mice, macrophage transplantation, and myeloid cell–specific GAL3-KO ( LysM Cre+/– Lgals3 fl/fl ) mice, we demonstrated that GAL3 in MDMø mediated acute infarct expansion after stroke. Coculturing brain lysate–treated, BM-derived macrophages (BMDMs) with oxygen glucose deprivation–challenged neurons induced neurotoxicity that was mitigated by the cell-permeable, selective GAL3 inhibitor TD139. GAL3 triggered cathepsin induction and lysosomal leakage in BMDMs, leading to inflammasome activation. Systemic and transient TD139 treatment in the acute injury phase reduced infarcts, tempered neuroinflammation, and improved long-term neurological outcomes. Therefore, MDMø-derived GAL3 represents a drug target that could be accessed in peripheral blood to potentially mitigate post-stroke brain injury.
- 17 February 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (8)
Open AccessGalectin-3 mediates lysosome-related inflammation within monocyte-derived macrophages in a mouse model of ischemic brain injury
Circulating monocyte-derived macrophages (MDMø) rapidly invade the brain after stroke, exerting both detrimental and beneficial effects. Elucidating mechanisms that mediate detrimental properties of MDMø may identify therapeutic strategies to divert MDMø from destructive phenotypes, while preserving their favorable effects. Toward this goal, the current study explores the function of Galectin-3 (GAL3) in MDMø and elucidates mechanisms whereby MDMø-derived GAL3 exacerbates stroke injury. In the acutely injured brain, GAL3 expression was upregulated primarily within MDMø. Global KO of GAL3 reduced brain infarcts in the short term but did not sustain long-term positive outcomes. Using BM chimera mice, macrophage transplantation, and myeloid cell–specific GAL3-KO ( LysM Cre+/– Lgals3 fl/fl ) mice, we demonstrated that GAL3 in MDMø mediated acute infarct expansion after stroke. Coculturing brain lysate–treated, BM-derived macrophages (BMDMs) with oxygen glucose deprivation–challenged neurons induced neurotoxicity that was mitigated by the cell-permeable, selective GAL3 inhibitor TD139. GAL3 triggered cathepsin induction and lysosomal leakage in BMDMs, leading to inflammasome activation. Systemic and transient TD139 treatment in the acute injury phase reduced infarcts, tempered neuroinflammation, and improved long-term neurological outcomes. Therefore, MDMø-derived GAL3 represents a drug target that could be accessed in peripheral blood to potentially mitigate post-stroke brain injury.
- 22 January 2026
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 46 (11) , 2913-2933
Monocyte-derived macrophages and their roles in ischemic stroke
Ischemic stroke causes rapid cellular distress and death in the central nervous system, leading its resident cells to disseminate diffusible inflammatory signals that can reach immune cells in distant peripheral tissues. Monocytes respond quickly to this distress signal and are among the earliest peripheral immune cell types to infiltrate the ischemic brain, where they differentiate into macrophages and critically contribute to brain injury and repair. Monocyte-derived macrophages (MDM) can be recruited from several different reservoirs throughout the body, and their phenotypes may differ by their origin and/or route of invasion. The objective of this review is to examine the roles of MDM in diverse processes that occur in a stroke injury, including phagocytosis, blood-brain barrier stabilization, inflammatory signal propagation and resolution, white matter repair, angiogenesis, and neurogenesis. We also describe how monocytes are mobilized in human patients and animal models of stroke, and their transformation into MDM. Although ischemic stroke therapies are currently limited to restoring blood flow, new strategies harnessing the CNS-invading and reparatory power of MDM are on the horizon. Hence, a better understanding of the molecular mechanisms that promote beneficial properties of MDM may optimize macrophage-targeting therapies for stroke in the future.
- 22 January 2026
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 46 (11) , 2913-2933
Monocyte-derived macrophages and their roles in ischemic stroke
Ischemic stroke causes rapid cellular distress and death in the central nervous system, leading its resident cells to disseminate diffusible inflammatory signals that can reach immune cells in distant peripheral tissues. Monocytes respond quickly to this distress signal and are among the earliest peripheral immune cell types to infiltrate the ischemic brain, where they differentiate into macrophages and critically contribute to brain injury and repair. Monocyte-derived macrophages (MDM) can be recruited from several different reservoirs throughout the body, and their phenotypes may differ by their origin and/or route of invasion. The objective of this review is to examine the roles of MDM in diverse processes that occur in a stroke injury, including phagocytosis, blood-brain barrier stabilization, inflammatory signal propagation and resolution, white matter repair, angiogenesis, and neurogenesis. We also describe how monocytes are mobilized in human patients and animal models of stroke, and their transformation into MDM. Although ischemic stroke therapies are currently limited to restoring blood flow, new strategies harnessing the CNS-invading and reparatory power of MDM are on the horizon. Hence, a better understanding of the molecular mechanisms that promote beneficial properties of MDM may optimize macrophage-targeting therapies for stroke in the future.
- Open Access
- 24 October 2024
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 21 (1) , 1-14
IL-33/ST2 signaling in monocyte-derived macrophages maintains blood-brain barrier integrity and restricts infarctions early after ischemic stroke
Brain microglia and infiltrating monocyte-derived macrophages are vital in preserving blood vessel integrity after stroke. Understanding mechanisms that induce immune cells to adopt vascular-protective phenotypes may hasten the development of stroke treatments. IL-33 is a potent chemokine released from damaged cells, such as CNS glia after stroke. The activation of IL-33/ST2 signaling has been shown to promote neuronal viability and white matter integrity after ischemic stroke. The impact of IL-33/ST2 on blood-brain barrier (BBB) integrity, however, remains unknown. The current study fills this gap and reveals a critical role of IL-33/ST2 signaling in macrophage-mediated BBB protection after stroke. Transient middle cerebral artery occlusion (tMCAO) was performed to induce ischemic stroke in wildtype (WT) versus ST2 knockout (KO) male mice. IL-33 was applied intranasally to tMCAO mice with or without dietary PLX5622 to deplete microglia/macrophages. ST2 KO versus WT bone marrow or macrophage cell transplantations were used to test the involvement of ST2+ macrophages in BBB integrity. Macrophages were cocultured in transwells with brain endothelial cells (ECs) after oxygen-glucose deprivation (OGD) to test potential direct effects of IL33-treated macrophages on the BBB in vitro. The ST2 receptor was expressed in brain ECs, microglia, and infiltrating macrophages. Global KO of ST2 led to more IgG extravasation and loss of ZO-1 in cerebral microvessels 3 days post-tMCAO. Intranasal IL-33 administration reduced BBB leakage and infarct severity in microglia/macrophage competent mice, but not in microglia/macrophage depleted mice. Worse BBB injury was observed after tMCAO in chimeric WT mice reconstituted with ST2 KO bone marrow, and in WT mice whose monocytes were replaced by ST2 KO monocytes. Macrophages treated with IL-33 reduced in vitro barrier leakage and maintained tight junction integrity after OGD. In contrast, IL-33 exerted minimal direct effects on the endothelial barrier in the absence of macrophages. IL-33-treated macrophages demonstrated transcriptional upregulation of an array of protective factors, suggesting a shift towards favorable phenotypes. Our results demonstrate that early-stage IL-33/ST2 signaling in infiltrating macrophages reduces the extent of acute BBB disruption after stroke. Intranasal IL-33 administration may represent a new strategy to reduce BBB leakage and infarct severity.
- 24 October 2024
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 21 (1) , 1-14
Open AccessIL-33/ST2 signaling in monocyte-derived macrophages maintains blood-brain barrier integrity and restricts infarctions early after ischemic stroke
Brain microglia and infiltrating monocyte-derived macrophages are vital in preserving blood vessel integrity after stroke. Understanding mechanisms that induce immune cells to adopt vascular-protective phenotypes may hasten the development of stroke treatments. IL-33 is a potent chemokine released from damaged cells, such as CNS glia after stroke. The activation of IL-33/ST2 signaling has been shown to promote neuronal viability and white matter integrity after ischemic stroke. The impact of IL-33/ST2 on blood-brain barrier (BBB) integrity, however, remains unknown. The current study fills this gap and reveals a critical role of IL-33/ST2 signaling in macrophage-mediated BBB protection after stroke. Transient middle cerebral artery occlusion (tMCAO) was performed to induce ischemic stroke in wildtype (WT) versus ST2 knockout (KO) male mice. IL-33 was applied intranasally to tMCAO mice with or without dietary PLX5622 to deplete microglia/macrophages. ST2 KO versus WT bone marrow or macrophage cell transplantations were used to test the involvement of ST2+ macrophages in BBB integrity. Macrophages were cocultured in transwells with brain endothelial cells (ECs) after oxygen-glucose deprivation (OGD) to test potential direct effects of IL33-treated macrophages on the BBB in vitro. The ST2 receptor was expressed in brain ECs, microglia, and infiltrating macrophages. Global KO of ST2 led to more IgG extravasation and loss of ZO-1 in cerebral microvessels 3 days post-tMCAO. Intranasal IL-33 administration reduced BBB leakage and infarct severity in microglia/macrophage competent mice, but not in microglia/macrophage depleted mice. Worse BBB injury was observed after tMCAO in chimeric WT mice reconstituted with ST2 KO bone marrow, and in WT mice whose monocytes were replaced by ST2 KO monocytes. Macrophages treated with IL-33 reduced in vitro barrier leakage and maintained tight junction integrity after OGD. In contrast, IL-33 exerted minimal direct effects on the endothelial barrier in the absence of macrophages. IL-33-treated macrophages demonstrated transcriptional upregulation of an array of protective factors, suggesting a shift towards favorable phenotypes. Our results demonstrate that early-stage IL-33/ST2 signaling in infiltrating macrophages reduces the extent of acute BBB disruption after stroke. Intranasal IL-33 administration may represent a new strategy to reduce BBB leakage and infarct severity.